Patent intelligence · US
US 8470312
Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
Patent details — US 8470312
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 25, 2013
- Expiration
- Jun 20, 2033
- Applicant
- ONCOLYTICS BIOTECH INC.
- Claims
- 20
- CPC classes
- A61K, A61K31/282, A61K31/555, A61K33/243
Quick answer
US 8470312 (Abrogating proinflammatory cytokine production during oncolytic reovirus therapy) is held by ONCOLYTICS BIOTECH INC.. Status: granted. Granted Jun 25, 2013. Expires Jun 20, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ONCOLYTICS BIOTECH INC.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/282, A61K31/555, A61K33/243, A61K35/765, A61P
More from ONCOLYTICS BIOTECH INC.
Related pharmaceutical patents in our USPTO index.
-
US 11542526
Oncolytic adenoviral vector and methods of use
granted -
US 11246930
Reoviruses having modified sequences
granted -
US 10596260
Reoviruses having modified sequences
granted -
US 10167452
Viral purification methods
granted -
US 10039827
Reoviruses having modified sequences
granted -
US 9610352
Lyophilized viral formulations
granted -
US 9610309
Liquid viral formulations
granted -
US 9365823
Virus clearance of neoplastic cells from mixed cellular compositions
granted
Frequently asked questions
What is US patent 8470312?
US 8470312 (Abrogating proinflammatory cytokine production during oncolytic reovirus therapy) is held by ONCOLYTICS BIOTECH INC.. Status: granted. Granted Jun 25, 2013. Expires Jun 20, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8470312?
ONCOLYTICS BIOTECH INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 66 pharmaceutical patents for this assignee.
When does US 8470312 expire?
Our index shows an expiration date of Jun 20, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.